Drug development projects of Motorpharma

Antispastic: MPH-220
MPH-220 is a next generation antispastic drug candidate targeting the contractile protein.
Clinical study of MPH-220
The clinical studies of MPH-220 will be sponsored and coordinated by Motric Bio Inc., USA
Click here for more information
Recovery after stroke
Our candidate repairs the damaged brain tissue through the formation of vascular and neuronal networks.
New drug candidate in preclinical stage
The preclinical studies of our MPH-S drug candidate are currently in progress.
Click here for more information

Our research

We at Motorpharma are keen on developing new generation drug candidates that open new dimensions to drug development. Our major pipeline project is MPH-220 that might be able to treat patients suffering from spasticity.

About 10% of the world suffers from the excruciating symptoms of spasticity caused by low back pain or neuro injury related diseases. Our drug development project is aiming at targeting directly the effector molecule of muscle contraction with drug candidates.

News

The Hungarian Forbes has made a report with us entering the first-in-human clinical phase with the compound MPH 220/MTR 601

"With a human trial pill in Texas, a small Hungarian drug discovery company is on the verge of global success."Click here for the link!

We are proud to be selected into the World of Forbes stories as the leading story of Hungary of 2021

Motorpharma's huge success of sub-licensing MPH-220 to Motric Bio was selected to the most important story of Hungary in 2021 by World of Forbes.  Click here for the link!